Search

Peter T Masiakos

from Sudbury, MA
Age ~60
Get Report
Related to:
Bessie Masiakos, 89Jim M Masiakos, 59
Connected to:
Johnthomas O Masian, 53Courtney R Masiarczyk, 32Angelo R Masias, 57Brian C Masias, 59Christopher M Masias, 49Cristian A Masias, 30Frank Masias, 78James A Masias, 62Javier R Masias, 65John D Masias, 73

Peter Masiakos Phones & Addresses

  • 36 Mossman Rd, Sudbury, MA 01776 (978) 443-3104
  • Brookline, MA
  • 3 Pond Street Pl, Boston, MA 02113 (617) 723-3862
  • 113 Endicott St, Boston, MA 02113 (617) 723-3862
  • 22 Reynolds Rd, Glen Cove, NY 11542 (516) 801-0294
  • Flushing, NY
  • Glen Head, NY

Work

Company: Pediatric Ambulatory Care Center Address: 2014 Washington St, Newton, MA 02462 Phones: (617) 243-6585

Education

School / High School: Boston University School Of Medicine 1994

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: General Surgery, 2005

Specialities

Pediatric Surgery

Professional Records

Medicine Doctors

Peter Masiakos Photo 1

Dr. Peter T Masiakos, Boston MA - MD (Doctor of Medicine)

View page
Specialties:
Pediatric Surgery
Address:
55 Fruit St, Boston, MA 02114
(617) 726-8839 (Phone), (617) 726-2167 (Fax)

Pediatric Ambulatory Care Center
2014 Washington St, Newton, MA 02462
(617) 243-6585 (Phone)
Certifications:
General Surgery, 2005
Pediatric Surgery, 2006
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
55 Fruit St, Boston, MA 02114

Pediatric Ambulatory Care Center
2014 Washington St, Newton, MA 02462

Massachusetts General Hospital
55 Fruit Street, Boston, MA 02114

Newton - Wellesley Hospital
2014 Washington Street, Newton, MA 02462
Education:
Medical School
Boston University School Of Medicine
Graduated: 1994
Peter Masiakos Photo 2

Peter T. Masiakos

View page
Description:
Dr. Masiakos graduated from the Boston University School of Medicine in 1994. He works in Newton Lower Falls, MA and 1 other location and specializes in Pediatric Surgery. Dr. Masiakos is affiliated with Massachusetts General Hospital and Newton-Wellesley Hospital.
Peter Masiakos Photo 3

Peter Theodore Masiakos, Boston MA

View page
Specialties:
Surgery
Pediatric Surgery
Trauma Surgery
Pediatric Hematology-Oncology
Work:
Massachusetts General Hospital
55 Fruit St, Boston, MA 02114
NWH - Pediatric Ambulatory Clinic
2000 Washington St 6 S, Newton Lower Falls, MA 02462
Education:
Boston University(1994)
Peter Masiakos Photo 4

Peter Theodore Masiakos, Boston MA

View page
Specialties:
Surgeon
Address:
55 Fruit St, Boston, MA 02114
Education:
Doctor of Medicine
Board certifications:
American Board of Surgery Certification in Surgery
American Board of Surgery Sub-certificate in Pediatric Surgery (Surgery)

Business Records

Name / Title
Company / Classification
Phones & Addresses
Peter Masiakos
Masiakos, Dr. Peter
Pediatric Surgeon
2014 Washington St, Newton Lower Falls, MA 02462
(617) 243-6585
Peter Masiakos
Vice-President
H P PRODUCTS CORP
Business Services at Non-Commercial Site · Heating & Air Conditioning/hvac
PO Box 63, Old Bethpage, NY 11804
11 Sorrel Hl Ct, Melville, NY 11747
(631) 643-4000

Publications

Us Patents

Delivery Of Therapeutic Biologicals From Implantable Tissue Matrices

View page
US Patent:
7078032, Jul 18, 2006
Filed:
Oct 21, 2003
Appl. No.:
10/690077
Inventors:
David T. MacLaughlin - Saugus MA, US
Joseph P. Vacanti - Winchester MA, US
Patricia K. Donahoe - Boston MA, US
Peter T. Masiakos - Boston MA, US
Assignee:
The General Hospital Corporation - Boston MA
International Classification:
A61K 48/00
A61K 9/14
A01N 63/00
C12N 5/00
C12N 15/63
C12P 21/06
C12N 15/00
US Classification:
424 9321, 424 931, 424 932, 424484, 435 691, 4353201, 435325, 435455
Abstract:
Normal cells, such as fibroblasts or other tissue or organ cell types, are genetically engineered to express biologically active, therapeutic agents, such as proteins that are normally produced in small amounts, for example, MIS, or other members of the TGF-beta family Herceptin™, interferons, and anti-angiogenic factors. These cells are seeded into a matrix for implantation into the patient to be treated. Cells may also be engineered to include a lethal gene, so that implanted cells can be destroyed once treatment is completed. Cells can be implanted in a variety of different matrices. In a preferred embodiment, these matrices are implantable and biodegradable over a period of time equal to or less than the expected period of treatment, when cells engraft to form a functional tissue producing the desired biologically active agent. Implantation may be ectopic or in some cases orthotopic. Representative cell types include tissue specific cells, progenitor cells, and stem cells.

Apparatus And Method For Preserving A Tissue Margin

View page
US Patent:
8523042, Sep 3, 2013
Filed:
Oct 21, 2010
Appl. No.:
12/909298
Inventors:
Peter T Masiakos - Sudbury MA, US
Andrew Rosenberg - Brookline MA, US
Henning Gaissert - Dover MA, US
Assignee:
The General Hospital Corporation - Boston MA
International Classification:
A61B 17/068
US Classification:
2271801, 2271761, 227 19
Abstract:
A cartridge for a surgical apparatus includes a housing having a slot configured to accommodate a blade. A plurality of fasteners is configured to be deployed by the housing. A first row of the plurality of fasteners is positioned on a first side of the slot and a second row of the plurality of fasteners is positioned on a second side of the slot. The first row of the plurality of fasteners is the nearest row of fasteners to the slot on the first side of the slot that are deployed by the housing, and the first row of the plurality of fasteners is spaced apart from the slot such that an undamaged tissue margin is formed on a section of tissue during operation of the surgical apparatus.

Delivery Of Therapeutic Biologicals From Implantable Tissue Matrices

View page
US Patent:
20020031500, Mar 14, 2002
Filed:
Jan 26, 2001
Appl. No.:
09/770339
Inventors:
David MacLaughlin - Saugus MA, US
Joseph Vacanti - Winchester MA, US
Patricia Donahoe - Boston MA, US
Peter Masiakos - Boston MA, US
International Classification:
A61K048/00
C12N005/06
US Classification:
424/093210, 435/325000
Abstract:
Normal cells, such as fibroblasts or other tissue or organ cell types, are genetically engineered to express biologically active, therapeutic agents, such as proteins that are normally produced in small amounts, for example, MIS, or other members of the TGF-beta family Herceptin™, interferons, andanti-angiogenic factors. These cells are seeded into a matrix for implantation into the patient to be treated. Cells may also be engineered to include a lethal gene, so that implanted cells can be destroyed once treatment is completed. Cells can be implanted in a variety of different matrices. In a preferred embodiment, these matrices are implantable and biodegradable over a period of time equal to or less than the expected period of treatment, when cells engraft to form a functional tissue producing the desired biologically active agent. Implantation may be ectopic or in some cases orthotopic. Representative cell types include tissue specific cells, progenitor cells, and stem cells. Matrices can be formed of synthetic or natural materials, by chemical coupling at the time of implantation, using standard techniques for formation of fibrous matrices from polymeric fibers, and using micromachining or microfabrication techniques. These devices and strategies are used as delivery systems via standard or minimally invasive implantation techniques for any number of parenterally deliverable recombinant proteins, particularly those that are difficult to produce in large amounts and/or active forms using conventional methods of purification, for the treatment of a variety of conditions that produce abnormal growth, including treatment of malignant and benign neoplasias, vascular malformations (hemangiomas), inflammatory conditions, keloid formation, abdominal or plural adhesions, endometriosis, congenital or endocrine abnormalities, and other conditions that can produce abnormal growth such as infection. Efficacy of treatment with the therapeutic biologicals is detected by determining specific criteria, for example, cessation of cell proliferation, regression of abnormal tissue, or cell death, or expression of genes or proteins reflecting the above.
Control profile
Peter T Masiakos from Sudbury, MA, age ~60 Get Report